IP Library Granted Patent US 7,890,183
Granted Patent B2
US 7,890,183 · App. 12/190,886 · Granted Feb 15, 2011

Treating parasites with electric fields

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,890,183
App. No.
12/190,886
Granted
Feb 15, 2011
Kind
B2
Abstract

Cells that are in the process division are vulnerable to damage by AC electric fields that have specific frequency and field strength characteristics. The selective disruption of rapidly dividing cells can therefore be accomplished by imposing an AC electric field in a target region for extended periods of time. Some of the cells that divide while the field is applied will be damaged, but the cells that do not divide will not be harmed. This selectively damages or disrupts rapidly dividing cells like parasites, but does not harm normal cells that are not dividing.

Claims (29)

1. A method of selectively destroying or inhibiting the growth of parasites located within a target region of a patient, comprising the steps of:

administering, to the patient, a therapeutic agent that targets the parasites, so that a therapeutically effective dose arrives in the target region;

capacitively coupling an AC electric field into the target region of the patient while the therapeutically effective dose is present at the target region, wherein the electric field has frequency characteristics that correspond to a vulnerability of the parasites, wherein the electric field is strong enough to damage or disrupt a significant portion of the parasites, and wherein the electric field leaves non-dividing cells located within the target region substantially unharmed; and

repeating the coupling step until a therapeutically significant portion of the parasites die.

2. The method of claim 1 , wherein the frequency of the electric field is about 10 MHz, and wherein the strength of the electric field in at least a portion of the target region is between 0.5 V/cm and 10 V/cm.

3. The method of claim 2 , wherein the strength of the electric field is about 2 V/cm.

4. The method of claim 1 , wherein the electric field has a first orientation during a first interval of time and a second orientation during a second interval of time, wherein at least a portion of the first interval of time and the second interval of time are mutually exclusive.

5. The method of claim 4 , wherein the first orientation is generally perpendicular to the second orientation.

6. The method of claim 5 , wherein the first interval of time is about 300 mS and the second interval of time is about 300 mS.

7. A method of selectively destroying or inhibiting the growth of parasites located within a target region, comprising the steps of:

capacitively coupling an AC electric field into the target region, wherein the frequency of the electric field is about 10 MHz, wherein the strength of the electric field in at least a portion of the target region is between 0.5 V/cm and 10 V/cm, wherein the electric field has frequency characteristics that correspond to a vulnerability of the parasites, wherein the electric field is strong enough to damage or disrupt a significant portion of the parasites, and wherein the electric field leaves non-dividing cells located within the target region substantially unharmed; and

repeating the coupling step until a therapeutically significant portion of the parasites die.

8. The method of claim 7 , wherein the strength of the electric field is about 2 V/cm.

9. The method of claim 7 , wherein the electric field has a first orientation during a first interval of time and a second orientation during a second interval of time, wherein at least a portion of the first interval of time and the second interval of time are mutually exclusive.

10. The method of claim 9 , wherein the first orientation is generally perpendicular to the second orientation.

11. The method of claim 10 , wherein the first interval of time is about 300 mS and the second interval of time is about 300 mS.

12. The method of claim 7 , further comprising the step of delivering a therapeutic agent to the target region so that a therapeutically effective dose of the agent is present in the target region while the coupling step is performed.

13. An apparatus for selectively destroying or inhibiting the growth of parasites located within a target region of a patient, the apparatus comprising:

a first pair of insulated electrodes, wherein each of the electrodes has a surface configured to facilitate capacitive coupling of an electric field into the patient's body; and

an AC voltage source operatively connected to the electrodes;

wherein the AC voltage source and the electrodes are configured so that, when the electrodes are placed against the patient's body and the AC voltage source is activated, an AC electric field is capacitively coupled into the target region of the patient via the electrodes,

wherein the frequency of the electric field is about 10 MHz, wherein the strength of the electric field in at least a portion of the target region is between 0.5 V/cm and 10 V/cm, wherein the imposed electric field has frequency characteristics that correspond to a vulnerability of the parasites, wherein the electric field is strong enough to damage or disrupt a significant portion of the parasites, and wherein the electric field leaves non-dividing cells located within the target region substantially unharmed.

14. The apparatus of claim 13 , wherein the strength of the electric field is about 2 V/cm.

15. The apparatus of claim 13 , wherein the surface of each of the electrodes is insulated from the AC voltage source by a dielectric coating that has a very high dielectric constant.

16. The apparatus of claim 13 , further comprising:

a second pair of insulated electrodes, each having a surface configured to facilitate capacitively coupling of an electric field into the patient's body; and

a switching mechanism that alternately applies the output of the AC voltage source to either (a) the first pair of electrodes or (b) the second pair of electrodes.

17. The apparatus of claim 16 , wherein the first pair of electrodes is oriented with respect to the second pair of electrodes so that the field that is coupled into the patient when the AC voltage is applied to the first pair of electrodes is roughly perpendicular to the field that is coupled into the patient when the AC voltage is applied to the second pair of electrodes.

18. The apparatus of claim 16 , wherein the surface of each of the electrodes is insulated from the AC voltage source by a dielectric coating that has a very high dielectric constant.

Assignments (17)
PATENT SECURITY AGREEMENT Recorded May 4, 2024
From: NOVOCURE GMBH (SWITZERLAND)
To: BIOPHARMA CREDIT PLC
Reel/Frame 067315/0399 →
RELEASE OF SECURITY INTEREST Recorded Apr 24, 2024
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: NOVOCURE GMBH
Reel/Frame 067211/0839 →
SECURITY INTEREST Recorded Nov 6, 2020
From: NOVOCURE GMBH
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 054344/0510 →
RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 45278 0825 Recorded Aug 25, 2020
From: BIOPHARMA CREDIT PLC
To: NOVOCURE LIMITED
Reel/Frame 053597/0335 →
RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 50395/0398 Recorded Aug 19, 2020
From: BPCR LIMITED PARTNERSHIP
To: NOVOCURE GMBH
Reel/Frame 053538/0623 →
OMNIBUS CONFIRMATION OF ASSIGNMENT AGREEMENT Recorded May 21, 2020
From: BIOPHARMA CREDIT PLC
To: BPCR LIMITED PARTNERSHIP
Reel/Frame 052741/0173 →
RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 045278/0825 Recorded Apr 14, 2020
From: BIOPHARMA CREDIT PLC
To: NOVOCURE LIMITED
Reel/Frame 052391/0549 →
RELEASE OF SECURITY INTEREST Recorded Apr 13, 2020
From: BIOPHARMA CREDIT PLC
To: NOVOCURE LIMITED
Reel/Frame 052383/0705 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2019
From: NOVOCURE LIMITED
To: NOVOCURE GMBH
Reel/Frame 050110/0098 →
SECURITY INTEREST Recorded May 6, 2019
From: NOVOCURE GMBH
To: BIOPHARMA CREDIT PLC
Reel/Frame 050395/0398 →
SECURITY INTEREST Recorded Feb 7, 2018
From: NOVOCURE LIMITED
To: BIOPHARMA CREDIT PLC
Reel/Frame 045284/0851 →
RELEASE OF SECURITY INTEREST Recorded Feb 7, 2018
From: BIOPHARMA SECURED INVESTMENTS III HOLDINGS CAYMAN LP
To: NOVOCURE LIMITED
Reel/Frame 044858/0416 →
SECURITY INTEREST Recorded Feb 7, 2018
From: NOVOCURE LIMITED
To: BIOPHARMA CREDIT PLC
Reel/Frame 045278/0825 →
SECURITY INTEREST Recorded Feb 2, 2015
From: NOVOCURE LIMITED
To: BIOPHARMA SECURED INVESTMENTS III HOLDINGS CAYMAN LP
Reel/Frame 034866/0402 →
CHANGE OF NAME Recorded Jan 23, 2015
From: STANDEN LIMITED
To: NOVOCURE LIMITED
Reel/Frame 034795/0933 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S NAME AND ADDRESS PREVIOUSLY RECORDED AT REEL: 021747 FRAME: 0673. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jan 18, 2015
From: PALTI, YORAM; GILADI, MOSHE
To: STANDEN LIMITED
Reel/Frame 034757/0504 →
RELEASE OF SECURITY INTEREST Recorded Dec 20, 2013
From: DEUTSCHE BANK TRUST COMPANY AMERICAS
To: NOVOCURE LIMITED
Reel/Frame 031866/0567 →